Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00205322 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00205322 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 45 participants.
The verdict
NCT00205322, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and lack of associated catheter-related complications.
Interventions
- DRUG chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00205322
The ClinicalTrials.gov registry entry for NCT00205322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin) is the first listed.
NCT00205322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00205322 about?
NCT00205322 is a clinical study titled "Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer". The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens. Additionally, the use of an oral rather than an infusional 5-fu regimen represents a clear advantage in terms of both patient convenience and...
What is the current status of trial NCT00205322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00205322?
The interventions under investigation include: chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin) (DRUG).
Who is sponsoring clinical trial NCT00205322?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.